Texas 2015 84th Regular

Texas House Bill HB2675 House Committee Report / Fiscal Note

Filed 02/02/2025

Download
.pdf .doc .html
                    LEGISLATIVE BUDGET BOARD    Austin, Texas      FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION            April 19, 2015      TO: Honorable Myra Crownover, Chair, House Committee on Public Health      FROM: Ursula Parks, Director, Legislative Budget Board     IN RE:HB2675 by Larson (relating to excepting manufacturers engaged in certain commercial research and development from certain provisions of the Texas Controlled Substances Act.), Committee Report 1st House, Substituted    No significant fiscal implication to the State is anticipated.  The bill would amend the Health and Safety Code to exempt chemical manufacturers engaged in certain specified commercial research and development from certain regulations. It is assumed any costs associated with implementing the provisions of the bill could be absorbed within existing resources and that any revenue loss associated with any associated fee exemptions would not be significant. Local Government Impact No significant fiscal implication to units of local government is anticipated.    Source Agencies:405 Department of Public Safety   LBB Staff:  UP, JAW, NB, AI    

LEGISLATIVE BUDGET BOARD
Austin, Texas
FISCAL NOTE, 84TH LEGISLATIVE REGULAR SESSION
April 19, 2015





  TO: Honorable Myra Crownover, Chair, House Committee on Public Health      FROM: Ursula Parks, Director, Legislative Budget Board     IN RE:HB2675 by Larson (relating to excepting manufacturers engaged in certain commercial research and development from certain provisions of the Texas Controlled Substances Act.), Committee Report 1st House, Substituted  

TO: Honorable Myra Crownover, Chair, House Committee on Public Health
FROM: Ursula Parks, Director, Legislative Budget Board
IN RE: HB2675 by Larson (relating to excepting manufacturers engaged in certain commercial research and development from certain provisions of the Texas Controlled Substances Act.), Committee Report 1st House, Substituted

 Honorable Myra Crownover, Chair, House Committee on Public Health 

 Honorable Myra Crownover, Chair, House Committee on Public Health 

 Ursula Parks, Director, Legislative Budget Board

 Ursula Parks, Director, Legislative Budget Board

HB2675 by Larson (relating to excepting manufacturers engaged in certain commercial research and development from certain provisions of the Texas Controlled Substances Act.), Committee Report 1st House, Substituted

HB2675 by Larson (relating to excepting manufacturers engaged in certain commercial research and development from certain provisions of the Texas Controlled Substances Act.), Committee Report 1st House, Substituted



No significant fiscal implication to the State is anticipated.

No significant fiscal implication to the State is anticipated.



The bill would amend the Health and Safety Code to exempt chemical manufacturers engaged in certain specified commercial research and development from certain regulations. It is assumed any costs associated with implementing the provisions of the bill could be absorbed within existing resources and that any revenue loss associated with any associated fee exemptions would not be significant.

Local Government Impact

No significant fiscal implication to units of local government is anticipated.

Source Agencies: 405 Department of Public Safety

405 Department of Public Safety

LBB Staff: UP, JAW, NB, AI

 UP, JAW, NB, AI